Current use of aminoglycosides: Indications, pharmacokinetics and monitoring for toxicity

Internal Medicine Journal

Volumn 41, Issue 6, 2011, Pages 441-449

  Avent, M L ^a,b   Rogers, B A ^a   Cheng, A C ^c,d,e   Paterson, D L ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Medication Services Queensland   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d ALFRED HOSPITAL   (Australia)

^e MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

Aminoglycoside nomogram; Bayesian; Computerized dose prediction; Gentamicin; Pharmacokinetic method

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN; KANAMYCIN; NEOMYCIN; NETILMICIN; PAROMOMYCIN; STREPTOMYCIN; TOBRAMYCIN;

ALGORITHM; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; AUSTRALIA; BACTERIAL INFECTION; BAYES THEOREM; CLINICAL PRACTICE; COMPARTMENT MODEL; COMPUTER PROGRAM; DRUG BLOOD LEVEL; DRUG COST; DRUG INDICATION; DRUG METABOLISM; DRUG MONITORING; DRUG USE; GRAM NEGATIVE INFECTION; HEALTH CARE PERSONNEL; HUMAN; INFECTION; INFORMATION TECHNOLOGY; LINEAR REGRESSION ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PHARMACIST; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVIEW; SCREENING TEST; STAFF TRAINING; SURGICAL INFECTION;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; DRUG MONITORING; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 79959609118     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2011.02452.x     Document Type: Review

References (38)

1. Begg EJ, Barclay ML. Aminoglycosides - 50years on. Br J Clin Pharmacol 1995; 39: 597-603.
2. Therapeutic Guidelines. Antibiotic, 14 edn. Melbourne: Therapeutic Guidelines; 2010.
3. Mandell GL, Bennett JE, Dolin R. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th edn. Philadelphia, PA: Churchill Livingstone/Elsevier; 2010.
4. Health Communication Network. Australian Medicines Handbook. Adelaide: Australian Medicines Handbook; 2010.
5. Burton ME, Shaw LM, Schentag JJ, Evans WE, eds. Applied Pharmacokinetics and Pharmacodynamics, Fourth edn. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006.
6. Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin North Am 2003; 17: 503-28.
7. Paterson DL, Robson JM, Wagener MM. Risk factors for toxicity in elderly patients given aminoglycosides once daily. J Gen Intern Med 1998; 13: 735-9.
8. Prezant TR, Agapian JV, Bohlman MC, Bu X, Oztas S, Qiu WQ etal. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat Genet 1993; 4: 289-94.
9. Kahlmeter G, Dahlager JI. Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother 1984; 13 (Suppl A): 9-22.
10. Guthrie OW. Aminoglycoside induced ototoxicity. Toxicology 2008; 249: 91-6.
11. Halmagyi GM, Fattore CM, Curthoys IS, Wade S. Gentamicin vestibulotoxicity. Otolaryngol Head Neck Surg 1994; 111: 571-4.
12. Pirozzo S, Papinczak T, Glasziou P. Whispered voice test for screening for hearing impairment in adults and children: systematic review. BMJ 2003; 327: 967.
13. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study. Int J Antimicrob Agents 2009; 34: 585-8.
14. Jana S, Deb JK. Molecular understanding of aminoglycoside action and resistance. Appl Microbiol Biotechnol 2006; 70: 140-50.
15. Doi Y, Arakawa Y. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin Infect Dis 2007; 45: 88-94.
16. Aggen JB, Armstrong ES, Goldblum AA, Dozzo P, Linsell MS, Gliedt MJ etal. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob Agents Chemother 2010; 54: 4636-42.
17. Barclay ML, Begg EJ, Hickling KG. What is the evidence for once-daily aminoglycoside therapy? Clin Pharmacokinet 1994; 27: 32-48.
18. Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996; 312: 338-45.
19. Freeman CD, Strayer AH. Mega-analysis of meta-analysis: an examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials. Pharmacotherapy 1996; 16: 1093-102.
20. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996; 124: 717-25.
21. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996; 37: 645-63.
22. Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341: 335-9.
23. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93-9.
24. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2, 184 adult patients. Antimicrob Agents Chemother 1995; 39: 650-5.
25. Zhanel GG, Hoban DJ, Harding GK. The postantibiotic effect: a review of in vitro and in vivo data. DICP 1991; 25: 153-63.
26. Wallace AW, Jones M, Bertino JS, Jr. Evaluation of four once-daily aminoglycoside dosing nomograms. Pharmacotherapy 2002; 22: 1077-83.
27. Aiken SK, Wetzstein GA. Once-daily aminoglycosides in patients with neutropenic fever. Cancer Control 2002; 9: 426-31.
28. Nicolau DP, Wu AH, Finocchiaro S, Udeh E, Chow MS, Quintiliani R etal. Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring. Ther Drug Monit 1996; 18: 263-6.
29. Horstkotte D, Follath F, Gutschik E, Lengyel M, Oto A, Pavie A etal. [Guidelines on prevention, diagnosis and treatment of infective endocarditis. Executive summary]. Rev Esp Cardiol 2004; 57: 952-62.
30. Sexton DJ, Tenenbaum MJ, Wilson WR, Steckelberg JM, Tice AD, Gilbert D etal. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. Clin Infect Dis 1998; 27: 1470-4.
31. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Jr, Bolger AF, Levison ME etal. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111: e394-434.
32. Matthews I, Kirkpatrick C, Holford N. Quantitative justification for target concentration intervention - parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br J Clin Pharmacol 2004; 58: 8-19.
33. Duffull SB, Kirkpatrick CM, Begg EJ. Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens. Br J Clin Pharmacol 1997; 43: 125-35.
34. Mohan M, Batty KT, Cooper JA, Wojnar-Horton RE, Ilett KF. Comparison of gentamicin dose estimates derived from manual calculations, the Australian 'Therapeutic Guidelines: Antibiotic' nomogram and the SeBA-GEN and DoseCalc software programs. Br J Clin Pharmacol 2004; 58: 521-7.
35. Sawchuk RJ, Zaske DE, Cipolle RJ, Wargin WA, Strate RG. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther 1977; 21: 362-9.
36. Paterson DL, Robson JM, Wagener MM, Peters M. Monitoring of serum aminoglycoside levels with once-daily dosing. Pathology 1998; 30: 289-94.
37. Bayard DS, Jelliffe RW. A Bayesian approach to tracking patients having changing pharmacokinetic parameters. J Pharmacokinet Pharmacodyn 2004; 31: 75-107.
38. Macdonald I, Staatz CE, Jelliffe RW, Thomson AH. Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery. Ther Drug Monit 2008; 30: 67-74.